187 related articles for article (PubMed ID: 19445540)
1. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
[TBL] [Abstract][Full Text] [Related]
2. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
Xu G; Xiang CQ; Lu Y; Kang XN; Wang WJ; Liao P; Ding Q; Zhang YF
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):858-60. PubMed ID: 18756995
[TBL] [Abstract][Full Text] [Related]
3. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
4. Screening for the serum differential proteins of renal cell carcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Liu JS; Li HZ; Zhang YS; Wang P; Yan WG; Xie J; Dong DX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun; 33(3):287-91. PubMed ID: 21718612
[TBL] [Abstract][Full Text] [Related]
5. Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern.
Wu DL; Zhang WH; Wang WJ; Jing SB; Xu YM
Technol Cancer Res Treat; 2008 Jun; 7(3):155-60. PubMed ID: 18473487
[TBL] [Abstract][Full Text] [Related]
6. [Screening urine markers of renal cell carcinoma using SELDI-TOF-MS].
Wu DL; Wang WJ; Guan M; Jin SB; Jin CR; Zhang YF
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(13):1092-5. PubMed ID: 15312509
[TBL] [Abstract][Full Text] [Related]
7. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons.
Won Y; Song HJ; Kang TW; Kim JJ; Han BD; Lee SW
Proteomics; 2003 Dec; 3(12):2310-6. PubMed ID: 14673781
[TBL] [Abstract][Full Text] [Related]
8. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F
J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251
[TBL] [Abstract][Full Text] [Related]
10. Identification of two new serum protein profiles for renal cell carcinoma.
Engwegen JY; Mehra N; Haanen JB; Schellens JH; Voest EE; Beijnen JH
Oncol Rep; 2009 Aug; 22(2):401-8. PubMed ID: 19578783
[TBL] [Abstract][Full Text] [Related]
11. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
12. [Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].
Wu DL; Zhang YF; Guan M; Liu WW; Xu YM; Jin SB; Zhang J; Jin CR; Lü Y
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):274-7. PubMed ID: 17760254
[TBL] [Abstract][Full Text] [Related]
13. [Identification of colorectal cancer using proteomic patterns in serum].
Zhao G; Gao CF; Song GY; Li DH; Wang XL
Ai Zheng; 2004 Jun; 23(6):614-8. PubMed ID: 15191657
[TBL] [Abstract][Full Text] [Related]
14. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.
Hara T; Honda K; Ono M; Naito K; Hirohashi S; Yamada T
J Urol; 2005 Oct; 174(4 Pt 1):1213-7. PubMed ID: 16145372
[TBL] [Abstract][Full Text] [Related]
15. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
Zhang GQ; Du J; Pang D
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
[TBL] [Abstract][Full Text] [Related]
16. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma.
Nuerrula Y; Rexiati M; Liu Q; Wang YJ
Cancer Biomark; 2015; 15(4):485-91. PubMed ID: 26406868
[TBL] [Abstract][Full Text] [Related]
18. [Serum proteomic spectra of esophageal squamous cell carcinoma patients analyzed with IMAC3 protein chip].
Liu CZ; Zhu PY; Shi MX; Liu JB; Liao P; Xiang CQ; Zhang YX; Wang WJ
Ai Zheng; 2008 Mar; 27(3):272-8. PubMed ID: 18334116
[TBL] [Abstract][Full Text] [Related]
19. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
